Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449167 | 1.00 | NAT1 (0.50) | NAT1MEN1KMT2AALDH1A1MAPT | |
| Acetic Acid SCHEMBL1448012 | 0.96 | NAT1 (0.47) | NAT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14226357 | 0.86 | NAT1 (0.50) | NAT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8171891 | 0.83 | MEN1 (0.53) | NAT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL12961165 | 0.83 | MEN1 (0.53) | NAT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11451864 | 0.82 | TDP1 (0.47) | NAT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11451865 | 0.82 | TDP1 (0.47) | NAT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8310453 | 0.82 | MEN1 (0.49) | NAT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL12892068 | 0.80 | CRHBP (0.53) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL8311447 | 0.80 | MMP3 (0.53) | MEN1KMT2AALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | FCGR1A, FCGR2A, FCGR3B | NAT1 3115/4885MEN1 3865/4885KMT2A 3373/4885 |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | FCGR1A, FCGR2A, FCGR3B | NAT1 3115/4885MEN1 3865/4885KMT2A 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.